ORCID Profile
0000-0002-3033-0452
Current Organisations
University Medical Center Utrecht
,
Institute for Basic Science
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Optica Publishing Group
Date: 13-03-2020
DOI: 10.1364/OL.386848
Abstract: We report on a peculiar propagation of bosons loaded by a short Laguerre–Gaussian pulse in a nearly flat band of a lattice potential. Taking a system of exciton polaritons in a kagome lattice as an ex le, we show that an initially localized condensate propagates in a specific direction in space, if anisotropy is taken into account. This propagation consists of quantum jumps, collapses, and revivals of the whole compact states, and it persists given any direction of anisotropy. This property reveals its signatures in the tight-binding model, and, surprisingly, it is much more pronounced in a continuous model. Quantum revivals are robust to the repulsive interaction and finite lifetime of the particles. Since no magnetic field or spin–orbit interaction is required, this system provides a new kind of easily implementable optical logic.
Publisher: Oxford University Press (OUP)
Date: 06-07-2023
Abstract: Low-dose colchicine reduces cardiovascular risk in patients with coronary artery disease (CAD), but absolute benefits may vary between in iduals. This study aimed to assess the range of in idual absolute benefits from low-dose colchicine according to patient risk profile. The European Society of Cardiology (ESC) guideline–recommended SMART-REACH model was combined with the relative treatment effect of low-dose colchicine and applied to patients with CAD from the Low-Dose Colchicine 2 (LoDoCo2) trial and the Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease (UCC-SMART) study (n = 10 830). In idual treatment benefits were expressed as 10-year absolute risk reductions (ARRs) for myocardial infarction, stroke, or cardiovascular death (MACE), and MACE-free life-years gained. Predictions were also performed for MACE plus coronary revascularization (MACE+), using a new lifetime model derived in the REduction of Atherothrombosis for Continued Health (REACH) registry. Colchicine was compared with other ESC guideline–recommended intensified (Step 2) prevention strategies, i.e. LDL cholesterol (LDL-c) reduction to 1.4 mmol/L and systolic blood pressure (SBP) reduction to 130 mmHg. The generalizability to other populations was assessed in patients with CAD from REACH North America and Western Europe (n = 25 812). The median 10-year ARR from low-dose colchicine was 4.6% [interquartile range (IQR) 3.6–6.0%] for MACE and 8.6% (IQR 7.6–9.8%) for MACE+. Lifetime benefit was 2.0 (IQR 1.6–2.5) MACE-free years, and 3.4 (IQR 2.6–4.2) MACE+-free life-years gained. For LDL-c and SBP reduction, respectively, the median 10-year ARR for MACE was 3.0% (IQR 1.5–5.1%) and 1.7% (IQR 0.0–5.7%), and the lifetime benefit was 1.2 (IQR 0.6–2.1) and 0.7 (IQR 0.0–2.3) MACE-free life-years gained. Similar results were obtained for MACE+ and in American and European patients from REACH. The absolute benefits of low-dose colchicine vary between in idual patients with chronic CAD. They may be expected to be of at least similar magnitude to those of intensified LDL-c and SBP reduction in a majority of patients already on conventional lipid-lowering and blood pressure–lowering therapy.
Location: United Kingdom of Great Britain and Northern Ireland
Location: Italy
No related grants have been discovered for Alexei Andreanov.